Subtype
Lung Neuroendocrine Carcinoma
CI-CAN-00003107Explore in graph →
389 active trials6 approved drugs6 evidence items
- NCIt
- C45569
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003107Explore in graph →
Clinical trials
1,113 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (158)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04730999 | Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung Cancer(CeLEBrATE) | completed | Phase 2 | 54 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT02978404 | Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases | completed | Phase 2 | 26 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 |
| Jun 28, 2024 |
| clinicaltrials |
| NCT02200757 | Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer | completed | Phase 2 | 135 | ImmunityBio, Inc.INDUSTRY | 3 | Jun 25, 2024 | clinicaltrials |
| NCT01941316 | Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients | completed | Phase 1 / Phase 2 | 78 | Cancer Research and Biostatistics Clinical Trials ConsortiumNETWORK | 1 | May 9, 2024 | clinicaltrials |
| NCT04742959 | Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 203 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Apr 26, 2024 | clinicaltrials |
| NCT04381910 | Irinotecan Hydrochloride Liposome Injection (LY01610) For Small Cell Lung Cancer | completed | Phase 2 | 66 | Luye Pharma Group Ltd.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT02247349 | BMS-986012 in Relapsed/Refractory SCLC | completed | Phase 1 / Phase 2 | 106 | Bristol-Myers SquibbINDUSTRY | 7 | Mar 5, 2024 | clinicaltrials |
| NCT00020202 | FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT03083691 | BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer | completed | Phase 2 | 90 | Lung Cancer Group CologneOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT04361825 | Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects(SUKSES-N4) | completed | Phase 2 | 42 | Se-Hoon LeeOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT03913455 | Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer | completed | Phase 2 | 24 | Shadia Jalal, MDOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT02312622 | Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer | completed | Phase 2 | 27 | Joel NealOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT02580994 | Pembrolizumab in Untreated Extensive SCLC(REACTION) | completed | Phase 2 | 125 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 3 | Dec 11, 2023 | clinicaltrials |
| NCT00057837 | Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer | completed | Phase 2 | 140 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jul 5, 2023 | clinicaltrials |
| NCT02359019 | MK-3475 as Maintenance Therapy in Extensive Stage SCLC | completed | Phase 2 | 45 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Oct 14, 2022 | clinicaltrials |
| NCT02945852 | Apatinib for Extensive Stage Small Cell Lung Cancer After Second/Third Line Chemotherapy. | completed | Phase 2 | 40 | Fan Yun, MDOTHER | 1 | Jul 19, 2022 | clinicaltrials |
| NCT04636762 | A Study of Concurrent Chemoradiation With Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC) | completed | Phase 2 | 40 | Second Xiangya Hospital of Central South UniversityOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT03365791 | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies | completed | Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 1 | May 27, 2022 | clinicaltrials |
| NCT01935336 | Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers | completed | Phase 2 | 171 | University of Colorado, DenverOTHER | 1 | Feb 11, 2022 | clinicaltrials |
| NCT02936323 | PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers | completed | Phase 1 / Phase 2 | 89 | Tarveda TherapeuticsINDUSTRY | 2 | Dec 14, 2021 | clinicaltrials |
| NCT00695292 | Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer | completed | Phase 2 | 37 | SCRI Development Innovations, LLCOTHER | 1 | Nov 22, 2021 | clinicaltrials |
| NCT03371979 | Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 68 | Aeglea BiotherapeuticsINDUSTRY | 2 | Nov 4, 2021 | clinicaltrials |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | completed | Phase 1 / Phase 2 | 515 | Gilead SciencesINDUSTRY | 1 | Aug 12, 2021 | clinicaltrials |
| NCT02674568 | Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer(TRINITY) | completed | Phase 2 | 342 | AbbVieINDUSTRY | 0 | Jul 30, 2021 | clinicaltrials |
| NCT03092934 | A Study of AK-01 (LY3295668) in Solid Tumors | completed | Phase 1 / Phase 2 | 13 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 2, 2021 | clinicaltrials |
| NCT02701400 | Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer | completed | Phase 2 | 18 | Emory UniversityOTHER | 1 | Jun 22, 2021 | clinicaltrials |
| NCT02593019 | Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients | completed | Phase 2 | 24 | Samsung Medical CenterOTHER | 1 | Mar 19, 2021 | clinicaltrials |
| NCT03325816 | Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 9 | Georgetown UniversityOTHER | 1 | Mar 16, 2021 | clinicaltrials |
| NCT03009682 | Olaparib Monotherapy in Relapsed Small Cell Lung Cancer Patients With HR Pathway Gene Mutations Not Limited to BRCA 1/2 Mutations, ATM Deficiency or MRE11A Mutations(SUKSES-B) | completed | Phase 2 | 15 | Samsung Medical CenterOTHER | 1 | Feb 18, 2021 | clinicaltrials |
| NCT03428607 | Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2] | completed | Phase 2 | 26 | Samsung Medical CenterOTHER | 1 | Feb 18, 2021 | clinicaltrials |
| NCT03059667 | Immunotherapy as Second-line in Patient With Small Cell Lung Cancer | completed | Phase 2 | 73 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Feb 10, 2021 | clinicaltrials |
| NCT03098030 | Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 483 | United TherapeuticsINDUSTRY | 23 | Dec 9, 2020 | clinicaltrials |
| NCT03547804 | A Prospective, Single-center, One-arm Clinical Study of Apatinib Combined With Chemotherapy for Pretreated Patients With Advanced Small Cell Lung Cancer(MK 01) | completed | Phase 2 | 31 | The First Hospital of Jilin UniversityOTHER | 1 | Dec 1, 2020 | clinicaltrials |
| NCT00415363 | Study of Enzastaurin Versus Placebo in the Treatment of Patients With Brain Metastases of Lung Cancer, After Whole Brain Radiation Therapy | completed | Phase 2 | 109 | Eli Lilly and CompanyINDUSTRY | 5 | Nov 5, 2020 | clinicaltrials |
| NCT02499770 | Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC) | completed | Phase 1 / Phase 2 | 122 | G1 Therapeutics, Inc.INDUSTRY | 7 | Aug 21, 2020 | clinicaltrials |
| NCT02289690 | Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 221 | AbbVieINDUSTRY | 12 | May 14, 2020 | clinicaltrials |
| NCT00080015 | Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC) | completed | Phase 2 | 9 | IpsenINDUSTRY | 0 | Apr 29, 2020 | clinicaltrials |
| NCT01876446 | Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer | completed | Phase 2 | 38 | Roswell Park Cancer InstituteOTHER | 1 | Mar 17, 2020 | clinicaltrials |
| NCT02735980 | A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer | completed | Phase 2 | 133 | Eli Lilly and CompanyINDUSTRY | 10 | Mar 17, 2020 | clinicaltrials |
| NCT00613626 | Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer | completed | Phase 2 | 74 | Hoosier Cancer Research NetworkOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT02551432 | Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer(MISP-MK3475) | completed | Phase 2 | 26 | Seoul National University HospitalOTHER | 1 | Feb 10, 2020 | clinicaltrials |
| NCT01880528 | Lisinopril in Reducing Shortness of Breath Caused by Radiation Therapy in Patients With Lung Cancer | completed | Phase 2 | 23 | Mayo ClinicOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT00388960 | Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer | completed | Phase 2 | 99 | CelgeneINDUSTRY | 5 | Nov 19, 2019 | clinicaltrials |
| NCT00617409 | To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid | completed | Phase 2 | 69 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 8, 2019 | clinicaltrials |
| NCT00375193 | Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy | completed | Phase 2 | 75 | CelgeneINDUSTRY | 3 | Oct 24, 2019 | clinicaltrials |
| NCT00483509 | Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma(NGR007) | completed | Phase 2 | 28 | AGC Biologics S.p.A.INDUSTRY | 1 | Oct 4, 2019 | clinicaltrials |
| NCT01025284 | A Study for Participants With Small-Cell Lung Cancer | completed | Phase 2 | 64 | Eli Lilly and CompanyINDUSTRY | 3 | Sep 17, 2019 | clinicaltrials |
| NCT01439568 | A Study of LY2510924 in Participants With Extensive-Stage Small Cell Lung Carcinoma | completed | Phase 2 | 90 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 23, 2019 | clinicaltrials |
| NCT03059797 | Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202) | completed | Phase 2 | 120 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 16, 2019 | clinicaltrials |
| NCT01253369 | Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 2 | 33 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 23, 2019 | clinicaltrials |
Data updated 22 days agoSource updated Jul 5, 2024source: clinicaltrials